Skip to content

Effectiveness of Unani Medicine for Eczema Treatment

Clinical Efficacy Of Unani Formulations Araq Mundi (Sphaeranthus Indicus) And Raughan Kamela (Mallotus Philipensis) In NarFarsi (Eczema): A Randomized Open Labelled Comparative Clinical Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099418
Enrollment
78
Registered
2025-12-18
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Araq Mundi(oral) Raughan Kamela(Topical): 1 Araq Mundi dosage form Extract,Dose 75ml once daily ,Mode Of Administration oral,Composition of Araq Mundi Gull e Mundi(spheranthus Indicus

Sponsors

Govt Unani Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age 18 years to 60years 2.Both gender 3.Diagnosis made on the basis of Hannifin and Rajka criteria 4.Eczema of mild to moderate in severity 5.Participants who have agreed to sign the informed consent form

Exclusion criteria

Exclusion criteria: 1.Participants below 18 and above 60 years of age 2.Participants with Autoimmune and other skin diseases 3.Eczema due to secondary infection 4.Pregnant and lactating women 5.Participant not willing to attend treatment schedule regularly

Design outcomes

Primary

MeasureTime frame
Reduction in EASI Score from baselineTimepoint: Baseline 2nd week 4th week 6th week

Secondary

MeasureTime frame
Improvement in DLQI Score from baseline Improvement in SCORAD from baselineTimepoint: Baseline 2nd week 4th week 6th week

Countries

India

Contacts

Public ContactDr Farzana Anjum A

Government Unani Medical College Chennai

muskaan.m@gmail.com9841620486

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026